BioCentury
ARTICLE | Company News

Biogen Idec, American Thrombosis and Hemostasis Network (ATHN), National Hemophilia Foundation, Puget Sound Blood Center hematology news

November 12, 2012 8:00 AM UTC

The entities partnered to offer free genotyping for hemophilia patients. The partnership will look to correlate the genotypic data with phenotypic data collected by ATHN. The blood center will be responsible for conducting the genotyping tests. Biogen Idec will provide financial support for the program as well as scientific advice and management support. The data will be entered into a database managed by ATHN. Biogen declined to provide details.

Last month, Biogen Idec and partner Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) reported top-line data from the Phase III A-LONG trial in 165 previously treated male hemophilia A patients aged 12 and older showing that rFVIIIFc as prophylaxis met the primary efficacy and safety endpoints. rFVIIIFc is a long-acting recombinant fusion protein consisting of the Fc domain of human IgG1 attached to Factor VIII. Biogen Idec plans to submit a BLA to FDA for rFVIIIFc next half. The partners are also developing rFIXFc, a recombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1. In September, the partners reported top-line data from the Phase III B-LONG trial in hemophilia B patients showing the compound met the primary efficacy and safety endpoints (see BioCentury, Oct. 1 & Nov. 5). ...